Ratings Takeda Pharmaceutical Company Limited

Equities

Market Closed - Japan Exchange Other stock markets 02:30:00 2025-07-07 EDT			5-day change	1st Jan Change
4,412.00 ^JPY	-0.63%		+1.05%	+5.52%

11:03am	US FDA approves KalVista's oral swelling disorder drug, shares rise	RE
06-30	Takeda Pharmaceutical Company Limited Announces U.S. FDA Approval of Gammard Liquid Immunoglobulin Therapy with Low Immunoglobulin A Content	CI

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
The company has a good ESG score relative to its sector, according to MSCI.

The company's profit outlook over the next few years is a strong asset.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The company's share price in relation to its net book value makes it look relatively cheap.
The company has a low valuation given the cash flows generated by its activity.
The company is one of the best yield companies with high dividend expectations.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
One of the major weak points of the company is its financial situation.
With a 2026 P/E ratio at 28.34 times the estimated earnings, the company operates at rather significant levels of earnings multiples.

Source: Surperformance

Source: MSCI

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Fundamentals (Composite)	Global Valuation (Composite)	Financial estimates revisions (Composite)	Capi.($)
	TAKEDA PHARMACEUTICAL COMPANY LIMITED				47.98B
	ELI LILLY AND COMPANY				701B
	JOHNSON & JOHNSON				375B
	ABBVIE INC.				334B
	NOVO NORDISK A/S				316B
	ROCHE HOLDING AG				263B
	NOVARTIS AG				242B
	ASTRAZENECA PLC				219B
	MERCK & CO., INC.				203B
	AMGEN INC.				160B
	Average				286.24B
	Weighted average by Cap.